TEVA Q2 2019 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.3B-7.7% YoY

Gross Profit

$1.9B43.7% margin

Operating Income

-$644M-14.8% margin

Net Income

-$689M-15.9% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+1.0%

Cash Flow

Operating Cash Flow

-$227M

Free Cash Flow

-$339M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$59.4B

Total Liabilities

$44.2B

Stockholders' Equity

$14.1B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.3B	$4.7B	-7.7%
Gross Profit	$1.9B	$2.1B	-8.1%
Operating Income	-$644M	-$14M	-4500.0%
Net Income	-$689M	-$176M	-291.5%

Revenue Segments

Anda

$351M49%

TREANDA and BENDEKA

$115M16%

Austedo

$96M14%

Pro Air

$65M9%

QVAR

$60M8%

AJOVY

$23M3%

Geographic Segments

North America

$1.7B59%

Europe

$1.2B41%